Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries?

摘要: The major goal of clinicians when treating acute musculoskeletal injuries is to return athletes their pre-injury level function, ideally in the shortest time possible and without compromising tissue-level healing. In this regard, a commonly used intervention taking NSAIDs. These are limit amount duration inflammation, control pain. While NSAIDs have become synonymous with management injuries, efficacy has yet be proven. This particular concern view recent research investigating latest class - selective cyclo-oxygenase-2 inhibitors (COXIBs). COXIBs were developed reduce adverse gastrointestinal (GI) effects traditional they beneficial anti-inflammatory analgesic properties, appear facilitate earlier function following injury, effect on healing currently unknown. experimental animal models been shown detrimental repair. Specifically, impair mechanical strength injury bone, ligament tendon. Clinically, may implications for ongoing morbidity future susceptibility. However, current studies limited translation clinical setting, particularly because significant limitations relating drug use dosage these studies. There no randomised, controlled trial evidence injuries. addition questions healing, further regarding agents raised given link being between one COXIB (rofecoxib) an increased risk cardiovascular events. Whether finding related individual properties rofecoxib or phenomenon subject investigation. light potential risks associated using COXIBs, acceptable possibly safer alternative Traditional do carry greater GI remain relatively not effects, effective pain relievers cheaper alternatives.